Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;14(10):694-700.
doi: 10.1177/1098612X12448017. Epub 2012 May 10.

Evaluation of lomustine as a rescue agent for cats with resistant lymphoma

Autumn L Dutelle  1 , Julie C Bulman-Fleming, Craig A Lewis, Mona P Rosenberg
Affiliations

Evaluation of lomustine as a rescue agent for cats with resistant lymphoma

Autumn L Dutelle et al. J Feline Med Surg. 2012 Oct.

Abstract

This retrospective study evaluated the use of lomustine as a rescue agent for 39 cases of resistant feline lymphoma. Parameters assessed included lymphocyte cell size, number of previous chemotherapy drugs and number of previous chemotherapy protocols received, time from lymphoma diagnosis to initiation of lomustine therapy, body weight and anatomic location of lymphoma. Cell size, number of previous chemotherapy drugs, number of previous chemotherapy protocols and anatomic location were all significant prognostic factors for the progression-free interval. Twenty-one cats (54%) received more than one dose of lomustine. The overall median progression-free interval (MPFI) was 39 days (range 7-708 days). The MPFI for large versus small and intermediate cell lymphomas was 21 versus 169 days, respectively. The MPFI for gastrointestinal versus non-gastrointestinal lymphomas was 180 versus 25.5 days, respectively. Lomustine has an acceptable efficacy and safety for use as a rescue agent in feline lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors do not have any potential conflicts of interest to declare.

Figures

Figure 1
Figure 1
Progression-free interval comparison between large cell lymphoma and non-large cell (small and intermediate) lymphoma cases. Large cell cases had a 9.8 times risk of disease progression compared to the small and intermediate cell cases (P = 0.00049). The median PFI of large cell cases was 21 days compared to 169 days for non-large cell cases
Figure 2
Figure 2
Progression-free interval comparison between patients receiving ≤6 previous chemotherapy drugs versus patients receiving ≥7 previous chemotherapy drugs. Cases that received more than six previous chemotherapy drugs had a 3.8 times increased risk of disease progression compared to cases receiving 1–6 previous chemotherapy drugs (P = 0.009). The median PFI for cases receiving 1–6 previous drugs was 46.5 days versus 27 days if they received more than six drugs
Figure 3
Figure 3
Progression-free interval comparison between patients receiving one or two previous protocols before beginning lomustine versus patients receiving three or four previous protocols before beginning lomustine. Cats that received 3–4 previous chemotherapy protocols were 3.6 times as likely to have disease progression compared to the cats that received 1–2 previous protocols (P = 0.02). The median PFI for cats that received 1–2 protocols was 31 days versus 77.5 days for cases receiving 3–4 previous protocols. However, if the cats survived past the median point, the cases with 1–2 previous protocols went on to stay on the protocol longer
Figure 4
Figure 4
Progression-free interval comparison between patients with GI lymphoma versus patients with non-GI lymphoma. Cats with non-GI lymphomas had a 4.7 times increased risk of disease progression compared to cases with GI lymphoma (P = 0.0018). The median PFI for cats with GI lymphoma was 180 days versus 25.5 days for cats with non-GI lymphoma
See this image and copyright information in PMC

References

    1. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy Principles and Practice. 4th edn. Philadelphia: Lippincott Williams and Wilkins, 2006.
    1. Finlay JL, Boyett JM, Yates AJ, et al.. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine and prednisone with the eight drugs in 1 day regimen. J Clin Oncol 1995; 13: 112–123. - PubMed
    1. Williams SD, Einhorn LH. Combination chemotherapy with doxorubicin and lomustine. Treatment of refractory Hodgkin’s disease. J Am Med Assoc 1977; 238: 1659–1661. - PubMed
    1. York RM, Foltz AT. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 1998; 1: 61: 2183–2186. - PubMed
    1. Williams LE, Rassnick KM, Power HT, et al.. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med 2006; 20: 136–143. - PubMed

Substances

LinkOut - more resources